

**FIAF Blocking Peptide**  
**Catalog # PBV10204b****Specification**

---

**FIAF Blocking Peptide - Product Information**

Primary Accession	<a href="#">Q9Z1P8</a>
Other Accession	<a href="#">BAC25242</a>
Gene ID	57875
Calculated MW	45538

**FIAF Blocking Peptide - Additional Information****Gene ID** 57875**Application & Usage**

The peptide is used for blocking the antibody activity of FIAF. It usually blocks the antibody activity completely in Western blot analysis by incubating the peptide with equal volume of antibody for 30-60 minutes at 37°C.

**Other Names**

Angiopoietin-related protein 4, 425O18-1, Angiopoietin-like protein 4, Fasting-induced adipose factor, Hepatic fibrinogen/angiopoietin-related protein, HFARP, Secreted protein Bk89, Angptl4, Farp, Fiaf, Ng27

**Target/Specificity**

FIAF

**Formulation**

50 µ (0.5 mg/ml) in phosphate buffered saline (PBS), pH 7.2, containing 50% glycerol, 1% BSA and 0.02% thimerosal.

**Reconstitution & Storage**

-20 °C

**Background Descriptions****Precautions**

FIAF Blocking Peptide is for research use only and not for use in diagnostic or therapeutic procedures.

**FIAF Blocking Peptide - Protein Information****Name** Angptl4**Synonyms** Farp, Fiaf {ECO:0000303|PubMed:10862772}

**Function**

Mediates inactivation of the lipoprotein lipase LPL, and thereby plays a role in the regulation of triglyceride clearance from the blood serum and in lipid metabolism (PubMed:<a href="http://www.uniprot.org/citations/15837923" target="\_blank">15837923</a>, PubMed:<a href="http://www.uniprot.org/citations/17609370" target="\_blank">17609370</a>, PubMed:<a href="http://www.uniprot.org/citations/29899519" target="\_blank">29899519</a>). May also play a role in regulating glucose homeostasis and insulin sensitivity (PubMed:<a href="http://www.uniprot.org/citations/15837923" target="\_blank">15837923</a>, PubMed:<a href="http://www.uniprot.org/citations/29899519" target="\_blank">29899519</a>). Inhibits proliferation, migration, and tubule formation of endothelial cells and reduces vascular leakage (PubMed:<a href="http://www.uniprot.org/citations/14583458" target="\_blank">14583458</a>, PubMed:<a href="http://www.uniprot.org/citations/17130448" target="\_blank">17130448</a>, PubMed:<a href="http://www.uniprot.org/citations/21832056" target="\_blank">21832056</a>). Upon heterologous expression, inhibits the adhesion of endothelial cell to the extracellular matrix (ECM), and inhibits the reorganization of the actin cytoskeleton, formation of actin stress fibers and focal adhesions in endothelial cells that have adhered to ANGPTL4-containing ECM (in vitro) (By similarity). Depending on context, may modulate tumor-related angiogenesis (Probable).

**Cellular Location**

Secreted. Secreted, extracellular space, extracellular matrix {ECO:0000250|UniProtKB:Q9BY76}. Note=The unprocessed form interacts with the extracellular matrix. This may constitute a dynamic reservoir, a regulatory mechanism of the bioavailability of ANGPTL4. {ECO:0000250|UniProtKB:Q9BY76}

**Tissue Location**

Detected in liver and kidney (PubMed:10698685, PubMed:17609370). Predominantly expressed in adipose tissue and is strongly up-regulated by fasting in white adipose tissue and liver

**FIAF Blocking Peptide - Protocols**

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

**FIAF Blocking Peptide - Images**